Letrozole, a targeted non-steroidal aromatase inhibitor, suppresses aromatase, leading to elevated testosterone levels and hyperandrogenism, replicating various PCOS phenotypes. The gene discussed is CYP19A1; the disease is polycystic ovary syndrome.